Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24936280 | 1.00 | CHEK1 (1.00) | CHEK1KCNH2 | |
| SCHEMBL29045156 | 1.00 | CHEK1 (1.00) | CHEK1KCNH2 | |
| SCHEMBL29632266 | 0.85 | CHEK1 (1.00) | CHEK1KCNH2 | |
| SCHEMBL24936278 | 0.85 | CHEK1 (1.00) | CHEK1KCNH2 | |
| SCHEMBL24936260 | 0.84 | CHEK1 (1.00) | CHEK1KCNH2 | |
| SCHEMBL29632531 | 0.84 | CHEK1 (1.00) | CHEK1KCNH2 | |
| SCHEMBL26668630 | 0.84 | CHEK1 (1.00) | CHEK1KCNH2 | |
| SCHEMBL24936199 | 0.83 | CHEK1 (0.71) | CHEK1KCNH2 | |
| SCHEMBL31022715 | 0.82 | CHEK1 (0.69) | CHEK1KCNH2 | |
| SCHEMBL25235197 | 0.82 | CHEK1 (0.69) | CHEK1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12410154-B2 | 5-heteroaryl-1H-pyrazol-3-amine derivative | Sumitomo Pharma Co., Ltd. (JP) | 2025-09-09 | — | — | US | claimed |
| CN-119403571-A | Therapeutic agent for cancer having therapeutic resistance to immune checkpoint inhibitor | 住友制药株式会社 | 2025-02-07 | — | — | CN | claimed |
| WO-2023229032-A1 | THERAPEUTIC FOR CANCER REFRACTORY TO IMMUNE CHECKPOINT INHIBITOR | 住友ファーマ株式会社 | 2023-11-30 | — | — | WO | claimed |
| CN-116546974-A | 5-heteroaryl-1H-pyrazol-3-amine derivatives | 住友制药株式会社 | 2023-08-04 | — | — | CN | claimed |
| WO-2022114189-A1 | 5-HETEROARYL-1H-PYRAZOL-3-AMINE DERIVATIVE | 住友ファーマ株式会社 | 2022-06-02 | — | — | WO | claimed |
| CN-119403571-A | Therapeutic agent for cancer having therapeutic resistance to immune checkpoint inhibitor | 住友制药株式会社 | 2025-02-07 | — | — | CN | disclosed |
| WO-2023229032-A1 | THERAPEUTIC FOR CANCER REFRACTORY TO IMMUNE CHECKPOINT INHIBITOR | 住友ファーマ株式会社 | 2023-11-30 | — | — | WO | disclosed |
| CN-116546974-A | 5-heteroaryl-1H-pyrazol-3-amine derivatives | 住友制药株式会社 | 2023-08-04 | — | — | CN | disclosed |
| WO-2022114189-A1 | 5-HETEROARYL-1H-PYRAZOL-3-AMINE DERIVATIVE | 住友ファーマ株式会社 | 2022-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12410154-B2 | 5-heteroaryl-1H-pyrazol-3-amine derivative | CHEK1, CHEK2, RB1 | CHEK1 1/4885KCNH2 2700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.